US 12,280,113 B2
Ras inhibitors
Elena S. Koltun, Foster City, CA (US); James Cregg, Belmont, CA (US); Yang Liu, Foster City, CA (US); and Adrian L. Gill, Atherton, CA (US)
Assigned to Revolution Medicines, Inc., Redwood City, CA (US)
Filed by Revolution Medicines, Inc., Redwood City, CA (US)
Filed on Mar. 23, 2023, as Appl. No. 18/188,966.
Application 18/188,966 is a continuation of application No. 17/476,269, filed on Sep. 15, 2021, granted, now 11,690,915, issued on Jul. 4, 2023.
Claims priority of provisional application 63/192,775, filed on May 25, 2021.
Claims priority of provisional application 63/184,412, filed on May 5, 2021.
Claims priority of provisional application 63/129,231, filed on Dec. 22, 2020.
Claims priority of provisional application 63/078,802, filed on Sep. 15, 2020.
Prior Publication US 2023/0226186 A1, Jul. 20, 2023
Int. Cl. A61K 45/06 (2006.01); A61P 35/00 (2006.01); C07D 417/14 (2006.01)
CPC A61K 45/06 (2013.01) [A61P 35/00 (2018.01); C07D 417/14 (2013.01)] 4 Claims
 
1. A compound of the following structure:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.